Related Experiment Videos
Interferon-alpha induced Raynaud's syndrome
W H Kruit1, A M Eggermont, G Stoter
1Department of Medical Oncology, Rotterdam Cancer Institute/University Hospital Rotterdam, The Netherlands. kruit@onch.azr.nl
Summary
Interferon-alpha (IFN-alpha) therapy can cause Raynaud's syndrome in patients with melanoma. This case study reviews symptoms, mechanisms, and treatments for this adverse effect.
Area of Science:
- Immunology
- Oncology
- Dermatology
Background:
- Interferon-alpha (IFN-alpha) is a cytokine used to treat viral hepatitis and malignancies.
- Adjuvant therapy with IFN-alpha is employed for high-risk melanoma.
- Adverse effects of IFN-alpha therapy require careful monitoring and management.
Observation:
- Two patients developed Raynaud's syndrome during IFN-alpha treatment for melanoma.
- Raynaud's syndrome is characterized by episodic vasospasm in extremities.
Findings:
- IFN-alpha may trigger Raynaud's syndrome through immune-mediated or direct vascular effects.
- Literature review details symptomatology, pathophysiology, and treatment options.
Implications:
- Clinicians should monitor for Raynaud's syndrome in patients receiving IFN-alpha.
- Early recognition and management can mitigate complications of IFN-alpha-induced Raynaud's syndrome.